NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $12.98 -1.06 (-7.55%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$12.80▼$14.2850-Day Range$12.70▼$24.2752-Week Range$11.66▼$42.60Volume53,676 shsAverage Volume83,890 shsMarket Capitalization$277.51 millionP/E RatioN/ADividend YieldN/APrice Target$43.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cartesian Therapeutics alerts: Email Address Cartesian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside231.3% Upside$43.00 Price TargetShort InterestBearish25.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 5 Articles This WeekInsider TradingAcquiring Shares$101,964 Bought Last QuarterProj. Earnings GrowthDecreasingFrom $3.99 to ($3.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.72 out of 5 starsMedical Sector390th out of 910 stocksPharmaceutical Preparations Industry174th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted25.13% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently increased by 0.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAC. Previous Next 1.7 News and Social Media Coverage News SentimentCartesian Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cartesian Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for RNAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $101,964.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders61.10% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cartesian Therapeutics are expected to decrease in the coming year, from $3.99 to ($3.49) per share.Read more about Cartesian Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Cartesian Therapeutics Stock (NASDAQ:RNAC)Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Read More RNAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAC Stock News HeadlinesAugust 15, 2024 | insidertrades.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys $101,963.52 in StockSeptember 6 at 7:05 AM | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . September 5 at 4:19 AM | americanbankingnews.comCartesian Therapeutics' (RNAC) "Buy" Rating Reaffirmed at HC WainwrightSeptember 3, 2024 | globenewswire.comCartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15August 14, 2024 | markets.businessinsider.comBuy Recommendation for Cartesian Therapeutics on Robust Clinical Trials and Favorable Regulatory ProspectsAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amid Clinical Success and Strengthened FinancialsAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian Therapeutics Amid Promising Clinical Trials and Regulatory ProspectsSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . August 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cartesian’s Innovative mRNA-based CAR-T Therapy Amidst Promising Clinical TrialsAugust 6, 2024 | msn.comTD Cowen Initiates Coverage of Cartesian Therapeutics (RNAC) with Buy RecommendationJuly 8, 2024 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsJuly 2, 2024 | globenewswire.comCartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikJuly 2, 2024 | investors.comCartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T DrugsJuly 2, 2024 | reuters.comCartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage studyJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces $130 Million Private Placement Equity FinancingJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusJuly 2, 2024 | globenewswire.comCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia GravisSee More Headlines Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CUSIPN/A CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$43.00 High Stock Price Target$50.00 Low Stock Price Target$39.00 Potential Upside/Downside+231.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-219,710,000.00 Net Margins-424.47% Pretax Margin-459.59% Return on EquityN/A Return on Assets-5.85% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual Sales$26 million Price / Sales10.67 Cash FlowN/A Price / Cash FlowN/A Book Value($82.38) per share Price / Book-0.16Miscellaneous Outstanding Shares21,380,000Free Float6,923,000Market Cap$277.51 million OptionableOptionable Beta0.65 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)President, CEO & Director Comp: $4.67MMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $2.49MDr. Metin Kurtoglu M.D. (Age 45)Ph.D., Chief Technology Officer Comp: $398.28kKey CompetitorsTyra BiosciencesNASDAQ:TYRAARS PharmaceuticalsNASDAQ:SPRYProthenaNASDAQ:PRTAAutolus TherapeuticsNASDAQ:AUTLPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsLogos Global Management LPBought 90,000 shares on 8/27/2024Ownership: 0.506%Point72 Asia Singapore Pte. Ltd.Bought 1,824 shares on 8/15/2024Ownership: 0.009%Marshall Wace LLPBought 30,038 shares on 8/14/2024Ownership: 0.140%Cubist Systematic Strategies LLCBought 13,010 shares on 8/14/2024Ownership: 0.061%Point72 DIFC LtdBought 1,725 shares on 8/14/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $20.6820 at the beginning of the year. Since then, RNAC shares have decreased by 37.2% and is now trading at $12.98. View the best growth stocks for 2024 here. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) announced its quarterly earnings data on Thursday, August, 8th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $1.35. The business had revenue of $33.45 million for the quarter, compared to the consensus estimate of $6 million. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics's stock reverse split on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Cartesian Therapeutics' major shareholders? Top institutional investors of Cartesian Therapeutics include Logos Global Management LP (0.42%), Logos Global Management LP (0.51%), Lake Street Advisors Group LLC (0.18%) and Marshall Wace LLP (0.14%). View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAC Stock Alerts